Figure 5. Plumbagin inhibits tumor growth in vivo.

(A) SMMC-7721 cells were subcutaneously injected into the right backs of female nude mice. After the tumors had grown to approximately 150 mm³–200 mm³, the mice received plumbagin (1.25 mg/kg/d, 2.5 mg/kg/d, or 5 mg/kg/d), saline (0.5 ml/d) or Thalidomide (200 mg/kg/d) every day for 30 d. (B) Photographs were taken of representative mice 30 days after treatment. (C) The tumor volumes are presented as the means ± SD of six mice as described in (A). (D) The tumor weights were measured 30 days after treatment. The data represent the mean values of six mice ± SE.*P < 0.05, **P < 0.01, ***p < 0.001 compared to the model group.